Ductal Adenocarcinoma: A Rare Entity of Prostate Gland in a Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patient

Kronik Lenfositik Lösemi/Küçük Hücreli Lenfositik Lenfomali Bir Hastada Prostatın Nadir Bir Antitesi: Duktal Adenokarsinoma

DOI: 10.4328/JCAM.3560  Received: 11.05.2015 Accepted: 23.05.2015 Printed: 01.10.2015  J Clin Anal Med 2015;6(suppl 5): 620-2

Corresponding Author: Tumay Ozgur, Pathology Department, Mustafa Kemal University, School of Medicine, 31100, Serinyol, Hatay, Turkey.
T.: +90 3262291000-3329 F.: +90 3262455654 E-Mail: ozgurtumay@yahoo.com

Abstract
Prostate cancer is the most common malignancy in men and ducal adenocarcinoma is a pathologic subtype with specific histological and clinical features. Seventy-six-year-old male patient with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) admitted to our hospital with lower urinary tract symptoms. The last prostate specific antigen (PSA) level was 26 ng/ml and serial transrectal ultrasound guided biopsies were administered and benign prostate hyperplasia and non-specific prostatitis were the results of pathology reports. Due to the persistence of the symptoms transurethral resection of the prostate was performed. In the pathologic evaluation of the material adenocarcinoma focuses without stroma has been observed between the hyperplasic prostate tissues. The tumor 4+4 Gleason patern skoru ile duktal adenokarsinom olarak tanı aild. Metastaza bağlı lomber vertebrada kemik sintigrafisinde aktivite tutulumu vardi. Bilgisayarlı tomografide onceki KLL/SLL ye bağlı inguinal ve sağ iliac lenfadenopati izlendi. Total androgen kısıtlama tedavisi ve bilateral orşiektomi uygulandı. 3 ay sonra biyomiyasal ve radyolojik görüntüleme sonuçlarına göre radyoterapi tedavisi planlandı. Duktal adenokarsinomuna konvansiyonel adenokarsinomdan farklı klinik davranışa olan prostatın nadir bir subtipidir. Diğer yandan KLL/SLL tabiki yapılan bir hasta sekonder bir malignemi olarak ortaya çıkmaz olguyu değerli kılndırdar.

Keywords
CLL/SLL; Ductal Adenocarcinoma; Prostate

This case was presented as a poster in Avrasian Urooncology congress in 2015.

Özet

Anatkar Kelmeler
Duktal Adenokarsinoma; KLL/SLL; Prostat

Tumay Ozgur1, Murat Mehmet Rifaioğlu2, Ahmet Taner Sümbül3, Füsun Aydoğan4, Nesrin Atcı5
1Pathology Department, Mustafa Kemal University, School of Medicine, 2Urology Department, Mustafa Kemal University, School of Medicine, 3Oncology Department, Adana Başkent University, School of Medicine, 4Nuclear Medicine Department, Mustafa Kemal University, School of Medicine, 5Radiology Department, Mustafa Kemal University, School of Medicine, Hatay, Turkey

This case was presented as a poster in Avrasian Urooncology congress in 2015.
Introduction
Ductal adenocarcinoma (DA) of the prostate is a rare histologic subtype of prostate cancer that was first defined by Melicow et al. as endometrial carcinoma of prostatic utricule in 1967 [1]. Prostate specific antigen levels (PSA) seem to be in normal levels and the behaviour of the tumor is uncertain [2]. DA usually presents with acinar adenocarcinoma and the pure form is rare constituting 0.4-0.8 % of all radical prostatectomy and biopsy specimens [3]. It may be misdiagnosed as various benign, precancerous and malign lesions like prostatic urethral polyps, high grade prostatic intraepithelial neoplasia (HG-PIN) and colorectal adenocarcinoma.

Postatic DA may originate either from large primary periurethral prostatic ducts or rarely from peripheral prostatic ducts [4].

We would like to describe our case which we diagnosed in transurethral resection specimen incidentally as DA with mild PSA levels and prostatism symptoms in a chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patient.

Case Report
Seventy-six year-old male patient with CLL/SLL admitted to Mustafa Kemal University hospital Urology department outpatient clinic with lower urinary tract symptoms. Prostate gland was 90 gram in ultrasonography (US) examination. The last total PSA and free PSA level was 23.3 and 5.7 ng/ml, respectively and three consecutive twelve core transrectal ultrasound guided biopsies were administered and benign prostate hyperplasia and non-specific prostatitis were the results of pathology reports. Due to the persistence of the symptoms transurethral resection of the prostate (TURP) was performed, during TURP procedure there was a papillary lesion protruded from right apex of the prostatic urethra and the material has been sent to pathology laboratory. In the microscopic evaluation of the specimen adenocarcinoma focuses without stroma has been observed between the hyperplasic prostate tissues (Figure 1). The nuclear morphology was different from classic acinar adenocarcinoma. To confirm the diagnosis and differentiate it from metastatic tumors an immunohistochemical panel was applied. While CK7, CK20 were negative, PSA and AMACR were positive in immunohistochemical studies (Figure 2-3). The tumor has been diagnosed as ductal adenocarcinoma with 4+4 Gleason pattern score. Bone scintigraphy was revealed activity uptake on lomber vertebral column. Computerized tomography was revealed previous bilateral inguinal and right iliac lymphadenopathy due to CLL. Total androgen deprivation therapy and orchiectomy was applied, after three mounts according to biochemical and imaging results, radiotherapy cure was began.

Discussion
Prostatic DA is a rare variant most commonly growing as exophytic mass lesions in the uretra. There are various mimickers of this entity that it should be recognised by pathologists and uropathologists in daily practice [4]. DAs are often localised at the central ducts of the gland. Therefore they are usually seen in TURP and radical prostatectomy specimens and less diagnosed in needle biopsies. Our case had also two serial transrectal US guided biopsies but final proce-
The cystourethoscopic appearance of DA is described as exophytic and polypoid mass projecting into the urethra or near the verumontanum [6]. Kan et al. defined 10 of their cases as intra luminal growth masses during cystoscopy in their review of Hong Kong DA series [2]. We have observed an exophytic mass lesion projecting into the lumen at the prostate apex with right wall laterization.

DA has benign and malign mimickers. Prostatic urethral polyp is a polypoid lesion lined by benign appearing prostatic glandular epithelium and it can be confused with DA in fragmented needle biopsies. HG-PIN cribriform type is a difficult entity that should be remembered in differential diagnosis. HG-PIN constitutes with micropapillary cores while DA presents with true papillary cores. Beside this DA is recognisable with distinct atypia and large, back to back glands and usually comedonecrosis. DA might be confused with colorectal carcinoma metastasis. The verification of the diagnosis need immunohistochemical studies like PSA and PSAP. Another tumoral lesion that we should remember is papillary urothelial carcinoma in differential diagnosis; the cribriform architecture of DA is missing and nuclei of the tumor cells are more pleomorphic [4]. In the microscopic evaluation of the specimen we have found tumor composed of cribiform and adenoid structures with atypical columnar cells between the hyperplastic prostatic tissues. We have immunostained the tumoral tissue by Cytokeratin 7 and 20, AMACR, P63 and PSA. While Cytokeratin 7, 20 were negative, AMACR and PSA were strong and diffuse positive confirming our diagnosis of prostatic DA. P63 was diminished in neoplastic ducts.

In the literature DA is defined as a more agressive neoplasm compared to aciner adenocarcinoma. DA is mostly graded as 4+4= 8 whereas in cases of mixed ductal and aciner patterns ductal component should be assigned to Gleason patern 4 according to Gleason histopathologic scoring system [2]. We have also reported our case as 4+4=8 with its morphologic architecture and ductal differentiation.

Kan et al. reported bone and rectum invasions in 7 of their 20 DAs [2]. Our patient has lomber vertebra metastasis and alive receiving radiotherapy with no morbidity. Engin et al. declared the incidence of multipl primary cancers as 0.83% among cancer patients [7]. CLL/SLL patients are candidates for developing a second cancer and an increased frequency of certain cancer types twice times more compared to normal population because of disease or therapy related immununspression. Tsimeridau et al. reported prostate carcinoma synchronous with CLL in 12.8 % of their series [8]. Our patient is also under follow-up for CLL/SLL for three years and developed DA after two years.

DA of the prostate has unique morphological, clinical features and agressive behaviour. It should be remembered in cases with non-specific pathologic findings in periferic prostate biopsies of patients with persisant lower urinary tract symptoms. We should also point out this rare entity with its occurrence during CLL/SLL follow-up.

Competing interests
The authors declare that they have no competing interests.

References

How to cite this article: